[Skip to Content]
[Skip to Content Landing]
Views 129
Citations 0
Comment & Response
April 2018

Uses of H.P. Acthar Gel in the Clinical Setting—Reply

Author Affiliations
  • 1College of Pharmacy, Oregon State University/Oregon Health & Science University, Portland
  • 2Department of Neurology, Oregon Health & Science University, Portland
  • 3MS Center of Excellence - West, VA Portland Health Care System, Portland, Oregon
  • 4Division of Nephrology and Hypertension, Department of Medicine, Oregon Health & Science University, Portland
JAMA Intern Med. 2018;178(4):583-584. doi:10.1001/jamainternmed.2017.8545

In Reply We thank Dr Otulana for his interest and response to our Research Letter.1 We agree that repository corticotropin (Acthar) may have a place in therapy for a small number of patients who cannot tolerate or do not respond to synthetic corticosteroids. While Acthar use in the Medicare program is attributable to a relatively small number of specialists, costs to the program are substantial. In 2015, Medicare spent nearly twice as much approximately $504 million) on Acthar for 3104 patients than it did on lisinopril prescriptions (approximately $253 million) for 7.8 million patients.2

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×